| 書目名稱 | Prescribing Hemodialysis | | 副標(biāo)題 | A Guide to Urea Mode | | 編輯 | Thomas A. Depner | | 視頻video | http://file.papertrans.cn/755/754851/754851.mp4 | | 叢書名稱 | Developments in Nephrology | | 圖書封面 |  | | 描述 | What regulation shall we have for the operation? Shall a man transfuse he knows not what. to correct he knows not what. God knows how (l)? Dr. Henry Stubbs Royal College of Physicians circa 1670 If dialysis therapy were a new phannaceutical product being evaluated by the FDA now, it might not be approved for marketing. The recommended dose, its potential toxicity, the side effects of under-or over-dialysis as well as its efficacy have been the subject of very few studies. The high mortality rate associated with the treatment may raise a few eyebrows. That it is a life-saving modality of treatment is undoubtedly true for more than 100,000 patients in the United States and for more than a million patients world- wide. Because dialysis has extended the lives of many people by a variable period of time, most nephrologists have "rested on their laurels" and did not vigorously pursue studies to optimize these treatments. But facts have a way of intruding in all our lives and the facts are that the overall mortality rate of dialysis patients in the United States is rising and stands close to 25% per year and is closer to 33% per year for patients between the ages of 65 and 74 (2). These m | | 出版日期 | Book 1991 | | 關(guān)鍵詞 | dialysis; kidney; physiology | | 版次 | 1 | | doi | https://doi.org/10.1007/978-1-4613-1509-4 | | isbn_softcover | 978-1-4612-8811-4 | | isbn_ebook | 978-1-4613-1509-4 | | copyright | Kluwer Academic Publishers 1991 |
The information of publication is updating
|
|
|Archiver|手機(jī)版|小黑屋|
派博傳思國際
( 京公網(wǎng)安備110108008328)
GMT+8, 2025-10-14 09:31
發(fā)表于 2025-3-21 17:38:37
